The AURORA-1 trial. Sparkling with hope for lupus nephritis. Will this make it easier for rheumatologists to prescribe a CNI? Can you overcome the sticker shock to examine the benefits and weaknesses of AURORA-1. Let’s dive in.
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.